



Safety and efficacy of ruxolitinib in patients with relapsed or refractory Hodgkin's lymphoma (R/R HL)

JAK1/2 inhibition




 **33** Patients with R/R HL

 **Ruxolitinib:** • 20 mg if platelet count $>200 \times 10^9/L$
• 15 mg if platelet count $75-200 \times 10^9/L$

Median number of ruxolitinib cycle: 4 (range 1-12)

 **9** 27.3% 6 cycles of ruxolitinib

 **6** 18.2% >6 cycles of ruxolitinib

Median follow-up  17.5 months

Primary endpoint

- Overall response rate: 3/32 (9.4%; 90%CI: 2.6-22.5%)

Secondary endpoints

- Best overall response rate: 6/32 (18.8%; 95%CI: 7.2-36.4%)
- Progression-free survival: 3.5 months (95%CI: 1.9-4.6)
- Duration of response: 7.7 months
- Overall survival: 27.1 months (95%CI: 14.4-27.1)
- Adverse events: 40 in 14 (42.4%) patients
25 \geq Grade 3